Showing 2871-2880 of 3223 results for "".
- Registration Now Open for Neuro-Optometric Rehabilitation Association Online Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-online-conference/2477928/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) online conference at www.nora2020.com. The conference will be available live online on Saturday, September 12–Sunday, September 13. All presentations will be av
- How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistancehttps://modernod.com/news/how-regenerons-covid-19-antibody-cocktail-cuts-the-risk-of-resistance/2477920/When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last w
- Lilly Begins Trial of Olumiant as Possible Coronavirus Treatmenthttps://modernod.com/news/lilly-begins-trial-of-olumiant-as-possible-coronavirus-treatment/2477899/Eli Lilly said Monday that the first patient has been enrolled in a phase 3 study testing its Incyte-partnered JAK1/JAK2 inhibitor Olumiant (baricitinib) in hospitalized adults with COVID-19. The trial, which will be conducted in
- FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquinehttps://modernod.com/news/fda-revokes-emergency-use-authorization-for-chloroquine-and-hydroxychloroquine/2477896/The FDA revoked the emergency use authorization (EUA) that allowed for chloroquine and hydroxychloroquine to be used to treat certain hospitalized patients with COVID-19, according to an FDA news release. The agency determined that th
- AstraZeneca to Supply Europe Up to 400 Million COVID-19 Vaccine Doseshttps://modernod.com/news/astrazeneca-to-supply-europe-up-to-400-million-covid-19-vaccine-doses/2479514/AstraZeneca announced that it has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of the University of Oxford’s COVID-19 experimental vaccine, with deliveries starting by the end of this year. CEO Pascal Soriot remarked that ̶
- Modernizing Medicine Introduces Modmed SynapSYS Development Platformhttps://modernod.com/news/modernizing-medicine-introduces-modmed-synapsys-development-platform/2479520/Modernizing Medicine has introduced modmed synapSYS, a new app development platform and suite of application programming interfaces (APIs). Modmed synapSYS was designed to allow third-party providers, healthcare institutions, and the developer community to easily interface Modernizing Medicine te
- AORN Releases Survey Results Exploring ORs’ Return to Pre-COVID-19 Surgical Volumeshttps://modernod.com/news/aorn-releases-survey-results-exploring-ors-return-to-pre-covid-19-surgical-volumes/2479521/The Association of periOperative Registered Nurses (AORN) announced survey results of more than 1,000 surgical nurse leaders in the United States regarding how their facilities are managing the resumption of elective surgeries. Key Findings The top three spec
- AstraZeneca Targeting Over 2 Billion COVID-19 Vaccine Doses After Latest Dealshttps://modernod.com/news/astrazeneca-targeting-over-2-billion-covid-19-vaccine-doses-after-latest-deals/2477865/AstraZeneca said it signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII) in a move aimed at broadening global access to an experimental COVID-19 vaccine being developed at the University of Oxford. The
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib